[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580961":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":42,"collaborators":11,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":11,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":11,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Malignant tumor","EXPERIMENTAL",null,[13],"Drug: 68GA-DOTA-dPNE",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","68GA-DOTA-dPNE","Intravenous administration of 68GA-DOTA-dPNE tracer",[9],[21],{"name":22,"affiliation":5,"role":23},"Xianzhong Zhang, PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Chenhao Jia","CONTACT","18548703382","jiachenhao24@163.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":11,"geoPoint":11,"contacts":39},"PUMCH","RECRUITING","Dongcheng","Beijing Municipality","100730","China","CN",[40],{"name":41,"role":27,"phone":28,"phoneExt":11,"email":29},"Chenhao JIA",{"type":43,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100580961","application-of-68ga-labeled-cd73-targeting-probe-petct-imaging-in-the-diagnosis-of-malignant-tumor-100580961",false,"NCT06844110","Application of 68GA-labeled CD73 Targeting Probe PET\u002FCT Imaging in the Diagnosis of Malignant Tumor","Inclusion Criteria:\n\n* 1: Age: ≥18 years, expected survival ≥12 weeks 2: Without radiotherapy and chemotherapy, surgery or biopsy is feasible to obtain pathological diagnosis 3: Standard Solid Tumor Response Evaluation Criteria (RECIST) version 1.1 with at least one measurable target lesion 4: Obtain written informed consent and be able to follow up\n\nExclusion Criteria:\n\n\\- 1: Severe liver and kidney dysfunction. 2: Women who are planning to conceive, pregnant, or breastfeeding, as well as those planning to have children during the study period, are not eligible to participate in this research. Women of childbearing potential must use effective contraception throughout the course of the study.\n\n3: Individuals unable to lie flat for thirty minutes. 4: Suffers from claustrophobia or other mental illnesses 5: Researchers believe that the subject has other conditions that make them unsuitable for inclusion in this study 6: Refuses to join this clinical study",true,"ALL","18 Years","70 Years",{"count":55,"type":56},50,"ESTIMATED","INTERVENTIONAL",[59],"NA","68Ga-DOTA-dPNE PET\u002FCT imaging was performed on patients with malignant tumors to observe the binding of lesions with the tracer and evaluate the expression of CD73. At the same time, correlation analysis was performed combined with relevant clinical indicators to evaluate the efficacy of 68Ga-DOTA-dPNE in the diagnosis and guidance of malignant tumor patients, and predict the response of targeted therapy.",[62],"Tumor Immunity","2025-07-31",{"date":65,"type":66},"2025-08-05","ACTUAL",{"date":68,"type":66},"2025-03-01",{"date":70,"type":56},"2026-03-30",{"name":5,"class":6},1]